Cargando…
Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer
Corticosteroids have been used in the therapy for castration-resistant prostate cancer (CRPC) for decades, both as monotherapy and in combination with additional agents. In this article the authors report the results of a phase II trial of dexamethasone versus prednisolone as monotherapy for CRPC. T...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622618/ https://www.ncbi.nlm.nih.gov/pubmed/25756508 http://dx.doi.org/10.1080/15384047.2014.1002687 |